Vitalbridge Capital Research
Investment Thesis
Vitalbridge Capital ("Bridging Vitality, Building The Future"; Chinese: 参赞生命力) is a Shanghai- and Hong Kong-based, China-focused US dollar venture capital firm founded in 2019 by Jinjian Zhang after a seven-year stint at Trustbridge Partners. The firm's philosophy centers on "Removing Noise to See the Signal": rather than chasing trends, Vitalbridge takes a thematic, top-down research approach to identify structural shifts driven by demographics, technology, and policy ("Mega Trends"), then looks for founders with the "vitality" (resilience, endurance, capacity for self-renewal) to solve the problems those shifts create. The firm summarizes its model as an equation: Signal Strength = Mega Trend x Founder Vitality, seeking "Founder-Market Fit" as the point of highest conviction.
Originally a broader digitalization/enterprise-services investor, Vitalbridge pivoted to AI in 2022, three years after founding. It now targets three core domains: (1) AI models and agent applications, (2) embodied AI (humanoid robotics, combining machine learning and computer vision for human-machine collaboration), and (3) AI-for-science, specifically biology and materials science applications. Founding Partner Jinjian Zhang frames the firm's regional thesis as: large-scale foundation models will remain US-led, while hardware and robotics will be China-dominated, with AI-powered robotics as the convergence point.
Stage Focus
Vitalbridge invests earliest, aiming to be the first institutional or external investor in its portfolio companies (pre-seed/angel through Series A), then follows on into growth rounds. It was the first US-dollar institutional investor in LimX Dynamics (March 2023) and the first investor in Spirit AI, Encos, Qingmao Intelligence, and Yixi.
Check Size
No specific check-size range is publicly disclosed. Fund II closed at USD 280.5M (exceeding its USD 275M hard cap), with an LP noting the fund's relatively small size gives it flexibility to invest in permissible, non-sanctioned areas. The firm takes large ownership stakes to maximize influence and secure clear liquidation terms.
Lead Tendency
Vitalbridge frequently leads or co-leads early rounds — it led the Pre-A round in LimX Dynamics and co-led Spirit AI's first round alongside Shunwei Capital — and takes large stakes to secure board influence and downside protection (e.g., drag-along rights used in the Chi Xiao/Cosmoplat exit).
Recent Activity
Fund III was soft-marketing as of September 2025, four years after Fund II's close, amid a difficult fundraising environment for China-focused USD VC. Investment activity has continued through 2026: Vast3D (Series B, Sept 2026), Aeroband (Series A, March 2026, Germany), Boli Technology (Series B, May 2025), LimX Dynamics (Series A, March 2025), and Spirit AI (Angel, August 2024). Portfolio company MiniMax listed on the Hong Kong Stock Exchange on January 9, 2026 (ticker 0100.HK), becoming the fastest AI company globally to go from founding to IPO (4 years), with market cap peaking above HKD 200 billion. LimX Dynamics closed a $200M Series B the same month and unveiled its TRON 2 humanoid robot and COSA embodied-intelligence operating system.
Portfolio Highlights
Notable companies: MiniMax (LLM/multimodal foundation models, HKEX-listed), LimX Dynamics (humanoid robotics, ~$296M total funding), Spirit AI (embodied AI/humanoid robots, national-certified benchmark leader), Hypershell (AI exoskeletons), PollyPolymer (advanced 3D-printing materials, national innovation award), Joyin/"Zeroth" (embodied intelligence consumer robots), SPEEDIANCE (smart fitness hardware, CES award winner), Encos (robotic joint modules), Qingmao Intelligence (AI infrastructure), Yixi (synthetic biology), BlockSec and Merlin Chain (blockchain security/infrastructure, pre-2022-pivot era), Cloopen (cloud communications, pre-IPO round), and Maycur (enterprise SaaS). The firm claims a 95% portfolio survival rate across 50+ investments and cites unrealized multiples of 8.4x on Encos and 5x on Spirit AI. Exits include a 1.6x/194% IRR sale of plasma-device maker Chi Xiao to Haier's Cosmoplat.
Team
- Jinjian Zhang — Founding Partner. Founded Vitalbridge in 2019 after seven years at Trustbridge Partners.
- Ivy Li — Partner, leads embodied AI coverage; joined from Australian Capital Equity in 2019.
- Chelsea Yan — Investor.
- Susan Song — CFO.
- Zhuoming Wang — Venture Partner.
The full team is roughly 20 people, including 10 investment professionals, all younger than the 37-year-old Zhang — a deliberate positioning as a "younger generation" investor able to connect with founders of similar age.
Decision Process
Partnership-driven; Zhang and partners like Ivy Li lead sector coverage (Li leads embodied AI). LPs describe the firm's edge as top-down thematic research rather than network- or deal-flow-driven sourcing.
Founder Preferences
Vitalbridge prioritizes founder resilience ("vitality") over pedigree alone — citing a Fund I enterprise-services investment that nearly failed during the SaaS downturn but survived to reach breakeven and $70-80M in projected revenue. The firm builds close, trust-based relationships with founders, framing itself as belonging to "the same new generation" as the entrepreneurs it backs.
Geographic Focus
China-focused, operating solely out of Shanghai and Hong Kong; tracks Chinese founders expanding overseas (Aeroband in Germany, Vast3D) but this represents a minority of deal flow. LP base is ~30-40% US, with most of the remainder from Europe; LPs include Adams Street Partners and Group Health Foundation.